Assessing adherence to an intravenous pantoprazole guideline

Journal of Pharmacy Technology

Volumn 22, Issue 1, 2006, Pages 15-21

  MacLaren, Robert ^a   Obritsch, Marilee D ^a   Sherman, Deborah S ^b   Jung, Rose ^a   Fish, Douglas N ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSAL DISEASE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SELECTION; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; STRESS RELATED MUCOSAL DISEASE; UPPER GASTROINTESTINAL BLEEDING;

EID: 32544432366     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250602200104     Document Type: Article

References (36)

1. Product monograph. Protonix IV (pantoprazole sodium IV). Philadelphia: Wyeth Laboratories. Revised July 2005.
2. MacLaren R. A review of stress ulcer prophylaxis. J Pharm Pract 2002;15:147-57.
3. American Society of Health-System Pharmacists Commission on Therapeutics. ASHP therapeutic guidelines on stress ulcer prophylaxis. Approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm 1999;56:347-79.
4. Jung R, MacLaren R. Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. Ann Pharmacother 2002;36:1929-37. DOI 10.1345/aph.1C151
5. Spirt MJ. Stress-related mucosal disease: risk factors and prophylactic therapy. Clin Ther 2004;26:197-213.
6. Steinberg KP. Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit. Crit Care Med 2002;30(6 suppl):S362-4.
7. Allen ME, Kopp BJ, Erstad BL. Stress ulcer prophylaxis in the postoperative period. Am J Health Syst Pharm 2004;61:588-96.
8. Zed PJ, Loewen PS, Slavik RS, Marra CA. Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers. Ann Pharmacother 2001;35:1528-34. DOI 10.1345/aph.1A028
9. 2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001;15:917-26.
10. Bardou M, Toubouti Y, Benhaberou-Brun D, Rahme E, Barkun AN. Meta-analysis: proton-pump inhibition decrease in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther 2005;21:677-86.
11. 2-antagonists or placebo for upper gastrointestinal bleeding with or without endoscopic hemostasis: a meta-analysis (abstract). Gastroenterol 2003;124:A-625.
12. Khuroo MS, Khuroo MS, Farahat KL, Kagevi IE. Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis. J Gastroenterol Hepatol 2005;20:11-25.
13. Barkun A, Bardou M, Marshall JK. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003;139:843-57.
14. Spirt MJ. Acid suppression in critically ill patients: what does the evidence support? Pharmacotherapy 2003;23(10 pt 2):87S-93S.
15. Pais SA, Yang R. Diagnostic and therapeutic options in the management of nonvariceal upper gastrointestinal bleeding. Curr Gastroenterol Rep 2003;5:476-81.
16. Pisegna JR. Treating patients with acute gastrointestinal bleeding or rebleeding. Pharmacotherapy 2003;23(10 pt 2):81S-6S.
17. 2-antagonists for treatment of GI bleeding. Ann Pharmacother 2003;37:433-7. DOI 10.1345/aph.1C115
18. Bustamante M, Stollman N. The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review. J Clin Gastroenterol 2000;30:7-13.
19. Erstad BL. Proton-pump inhibitors for acute peptic ulcer bleeding. Ann Pharmacother 2001;35:730-40. DOI 10.1345/aph.10306
20. Conrad SA. Acute upper gastrointestinal bleeding in critically ill patients: causes and treatment modalities. Crit Care Med 2002;30(6 suppl):S365-8.
21. Morgan D. Intravenous proton pump inhibitors in the critical care setting. Crit Care Med 2002;30(6 suppl):S369-72.
22. Cash BD. Evidence-based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med 2002;30(6 suppl):S373-8.
23. Gagnon YM, Levy AR, Eloubeidi MA, Arguedas MR, Rioux KP, Enns RA. Cost implications of administering intravenous proton pump inhibitors to all patients presenting to the emergency department with peptic ulcer bleeding. Value Health 2003;6:457-64.
24. Enns RA, Gagnon YM, Rioux KP, Levy AR. Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 2003;17:225-33.
25. Erstad BL. Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding. Crit Care Med 2004;32:1277-83.
26. Julapalli VR, Graham DY. Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Dig Dis Sci 2005;50:1185-93.
27. Barkun A, Fallone CA, Chiba N, et al. A Canadian clinical practice algorithm for the management of patients with nonvariceal upper gastrointestinal bleeding. Can J Gastroenterol 2004;18:605-9.
28. Barkun AN, Herba K, Adam V, Kennedy W, Fallone CA, Bardou M. The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding. Aliment Pharmacol Ther 2004;20:195-202.
29. McCarthy DM. Management of bleeding peptic ulcer: current status of intravenous proton pump inhibitors. Best Pract Res Clin Gastroenterol 2004;18(suppl):7-12.
30. van Rensberg CJ, Hartmann M, Thorpe A, et al. Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer. Am J Gastroenterol 2003;98:2635-41.
31. 2-receptor antagonist in intensive care unit patients (abstract). Crit Care Med 2001;29:A147.
32. Cornish P, Papastergiou J, Saibil F. Audit of IV pantoprazole: patterns of use and compliance with guidelines. Can J Hosp Pharm 2002;55:20-6.
33. Kaplan GG, Bates D, McDonald D, Romagnuolo J. Inappropriate use of intravenous proton pump inhibitors: problem extent and cost implications (abstract). Am J Gastroenterol 2002;97:S236.
34. Chan EP, Goebig M, Demers RF, Katzka DA, Metz DC. Intravenous (IV) pantoprazole to prevent rebleeding after endoscopic hemostasis of bleeding ulcers: initial US experience (abstract). Gastroenterol 2003;124:A626.
35. Guda NM, Noonan M, Kreiner MJ, Partington S, Vakil N. Use of intravenous proton pump inhibitors in the community practice: an explanation for the shortage. Am J Gastroenterol 2004;99:1233-7.
36. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experiences and research evidence in the adoption of clinical practice guidelines. CMAJ 1997;157:408-16.